← All trials
NCT05970744
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 10, 2023
- Primary completion
- Jun 19, 2023
- Completion date
- Sep 17, 2023
- First posted
- Aug 1, 2023
- Last posted
- Aug 15, 2023
- Enrollment
- 60
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Research Institute of Influenza, RussiaLead sponsor
- Research Institute of Influenza, RussiaOverall official - principal investigator
- Research Institute of Influenza, RussiaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.